文献速递胸部肿瘤放疗姑息放疗与转移瘤

III期非小细胞肺癌放化疗与免疫治疗后肺炎的诊断与管理

Diagnosis and management of pneumonitis following chemoradiotherapy and immunotherapy in stage III non-small cell lung cancer.
PubMed 文献 · Radiother Oncol · 2024-02-09

本研究在学术医学中心回顾性纳入2018至2021年接受放化疗和辅助度伐利尤单抗治疗的45例III期非小细胞肺癌患者,由放射科医生和胸部肿瘤科医生对CT扫描、放疗剂量分布和临床症状进行结构化多学科复核。结果显示,放射科医生复核仅6/45例(13.3%)诊断为免疫相关性肺炎,胸部肿瘤科医生复核仅4/45例(8.9%)诊断,另有3例(6.7%)疑似免疫相关性肺炎被否定。作者认为多学科评估减少了免疫相关性肺炎的诊断,并强调需多学科复核以避免不恰当地停止辅助免疫治疗。

要点

  • 45例患者中14例(31.1%)病历记录肺炎,11例(24.4%)停用度伐利尤单抗。
  • 放射科医生复核仅6例(13.3%)诊断免疫相关性肺炎。
  • 胸部肿瘤科医生复核仅4例(8.9%)诊断免疫相关性肺炎,另有3例(6.7%)疑似诊断被否定。

核心结论

  • 在采用PACIFIC方案治疗的患者中,对CT扫描、放疗剂量和患者症状进行多学科评估后,免疫相关性肺炎的诊断减少至8.9%。
  • 本研究强调在放化疗后接受辅助免疫治疗的患者中准确诊断免疫相关性或放射性肺炎的挑战,并突出多学科复核以避免不恰当停止辅助免疫治疗的必要性。

研究设计与样本

  • 在学术医学中心开展的回顾性研究,纳入2018至2021年接受放化疗和辅助度伐利尤单抗治疗的III期非小细胞肺癌患者。
  • 由经验丰富的胸部放射科医生复核基线和随访胸部CT,使用已发表的分类系统(Veiga C, Radiother Oncol 2018)系统评分疑似肺炎的影像学特征,并可查看放疗剂量分布截图。
  • 由两名经验丰富的胸部肿瘤科医生复核每例患者的病历、CT扫描和放疗野,最终形成结合专家临床医生和放射科医生意见的共识诊断。

主要发现

  • 纳入的45例患者中,14/45例(31.1%)病历记录肺炎,11/45例(24.4%)停用度伐利尤单抗。
  • 放射科医生复核后仅6/45例(13.3%)诊断为免疫相关性肺炎。
  • 胸部肿瘤科医生复核后仅4/45例(8.9%)诊断为免疫相关性肺炎。
  • 在胸部肿瘤科医生复核患者放疗野后,另有3例(6.7%)疑似免疫相关性肺炎被否定。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In inoperable stage III NSCLC, the standard of care is chemoradiotherapy and adjuvant durvalumab (IO) for 12 months. Pneumonitis is the commonest toxicity leading to discontinuation of IO. A failure to distinguish between expected radiation-induced changes, IO pneumonitis and infection can lead to unnecessary durvalumab discontinuation. We investigated the use of a structured multidisciplinary review of CT-scans, radiation dose distributions and clinical symptoms for the diagnosis of IO pneumonitis. METHODS: A retrospective study was conducted at an academic medical center for patients treated for stage III NSCLC with chemoradiotherapy and adjuvant durvalumab between 2018 and 2021. An experienced thoracic radiologist reviewed baseline and follow-up chest CT-scans, systematically scored radiological features suspected for pneumonitis using a published classification system (Veiga C, Radioth Oncol 2018), and had access to screenshots of radiation dose distributions. Next, two experienced thoracic oncologists reviewed each patients' case record, CT-scans and radiation fields. A final consensus diagnosis incorporating views of expert clinicians and the radiologist was made. RESULTS: Among the 45 included patients, 14/45 (31.1%) had a pneumonitis scored in patient records and durvalumab was discontinued in 11/45 cases (24.4%). Review by the radiologist led to a diagnosis of immune-related pneumonitis only in 6/45 patients (13.3%). Review by pulmonary oncologists led to a diagnosis of immune-related pneumonitis in only 4/45 patients (8.9%). In addition a suspicion of an immune-related pneumonitis was rejected in 3 separate patients (6.7%), after the thoracic oncologists had reviewed the patients' radiation fields. CONCLUSIONS: In patients treated using the PACIFIC regimen, multidisciplinary assessment of CT-scans, radiation doses and patient symptoms, resulted in fewer diagnoses of immune-related pneumonitis (8.9%). Our study underscores the challenges in accurately diagnosing either IO-related or radiation pneumonitis in patients undergoing adjuvant immunotherapy after chemoradiotherapy and highlights the need for multidisciplinary review in order to avoid inappropriate cessation of adjuvant IO.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Smesseim I, Mets OM, Daniels JMA, et al. Diagnosis and management of pneumonitis following chemoradiotherapy and immunotherapy in stage III non-small cell lung cancer. Radiother Oncol. 2024. PMID: 38341099. doi:10.1016/j.radonc.2024.110147

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。